Genfit flags U.S. peak annual sales above USD 1.5 billion for NIS-based MASH diagnostic tests by 2033, IQVIA says

• Genfit outlined a US market outlook for its NIS-based blood diagnostics to identify “at-risk” MASH patients; no new clinical results were disclosed.
• IQVIA analysis projected peak annual US test sales above USD 1.5 billion by 2033, supporting a long-term royalty stream.
• Adoption catalysts cited included Medicare reimbursement for Labcorp’s NASHnext from August 2026, broader guideline inclusion, rising disease awareness.
• Testing demand expected to accelerate from 2028 as additional MASH drugs reach the market, increasing patient identification and monitoring needs.
• Commercial update coincided with upcoming presentations at Liver Forum and Paris MASH Meeting; no specific study readouts were scheduled.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090130OMX_____CNEWS_FR_GNW1001261717_fr) on September 09, 2026, and is solely responsible for the information contained therein.